Internal Reference Number: FOI_7473
Date Request Received: 09/10/2023 00:00:00
Date Request Replied To: 01/11/2023 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Researcher
| Question Number 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab Monotherapy • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nitedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: Q. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5 • Amivantamab 0 • Atezolizumab Monotherapy <5 • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0 • Dabrafenib + Trametinib <5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 • Durvalumab <5 • Gemcitabine 0 • Nitedanib + Docetaxel 0 • Nivolumab <5 • Osimertinib <5 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0 • Paclitaxel 0 • Pembrolizumab Monotherapy <5 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5 • Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib <5 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy <5 (Cisplain/gemcitabine) • Palliative care only - Unable to answer, information not held | |
| Question Number 2: Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part. | |
| Answer To Question 2: no | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
